Related Experiment Video
Updated: Apr 14, 2026
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Trends in the early investigational drug development and areas for improvement
1Campus Bio-Medico University of Rome, Medical Oncology , Rome , Italy g.tonini@unicampus.it.
Abstract:
The continuous discovery of 'druggable' protein involved in different signal transduction pathways and aberrant tumorigenic processes, has led to rapid progress in drug development. Nowadays several agents interfering with intriguing pathways are in early- and late-phase clinical development. Alteration in the cyclin-dependent kinase-retinoblastoma protein pathway is frequent in various types of cancer. In breast cancer, CDK 4/6 inhibitors have shown robust anticancer potencies, both in in vitro and in vivo studies. Numerous PI3K inhibitors have been developed and are in varying stages of clinical testing involving different and complementary therapeutic strategies in an effort to circumvent multiple pathway redundancies and pathway crosstalk. The molecular chaperone heat shock protein 90 targeted inhibition could lead to the blockade of multiple oncogenic signaling pathways in tumor cells, making it an attractive opportunity in the treatment of human malignancies. The acquired resistance to EGFR-tyrosine kinase inhibitors stimulates the development of several new drugs. Finally, among promising molecules, Janus-associated kinase inhibitors have been found to play a crucial role in the pathophysiology of cancer in combination with traditional and/or experimental treatment. This editorial gives an overview on the state-of-art development of different strategies in the targeted therapies scenario.
Insights
Targeted therapies are advancing cancer treatment by inhibiting key proteins like CDK4/6, PI3K, HSP90, and JAK. These drugs show promise in clinical trials for various malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Drug development is rapidly progressing due to the identification of 'druggable' proteins in cancer signaling pathways.
- Aberrant signaling pathways are frequently altered in various cancers, presenting therapeutic targets.
Discussion:
- Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors demonstrate significant anticancer effects in breast cancer.
- Phosphoinositide 3-kinase (PI3K) inhibitors are in clinical trials, employing diverse strategies to overcome pathway redundancies.
- Heat shock protein 90 (HSP90) inhibitors offer a promising approach by blocking multiple oncogenic pathways.
- Resistance to Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors drives the development of new therapeutic agents.
- Janus-associated kinase (JAK) inhibitors are crucial in cancer pathophysiology and hold potential in combination therapies.
Key Insights:
- Targeted therapies are a rapidly evolving field in cancer treatment.
- Inhibitors of CDK4/6, PI3K, HSP90, EGFR, and JAK represent key strategies in current drug development.
- Overcoming drug resistance and pathway crosstalk are critical challenges addressed by novel therapeutic approaches.
Outlook:
- Continued research into targeted therapies is essential for improving cancer patient outcomes.
- Combination strategies involving targeted agents and traditional treatments are being explored.
- The development of next-generation inhibitors aims to enhance efficacy and circumvent resistance mechanisms.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
Related Concept Videos
01:26Drug Discovery: Overview
01:28Preclinical Development: Overview
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
01:11Clinical Trials: Overview
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...